NCT00143572View on ClinicalTrials.gov

Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Anemia, Sickle Cell
Interventions
DRUG

Magnesium Pidolate, Hydroxyurea

Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00143572 - Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease | Biotech Hunter | Biotech Hunter